VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
NXTS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
NXTSNexentis Technologies Inc.
$1.82$29101
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
NXTS logo

Nexentis Technologies Inc.

NXTS
NASDAQ · Oncology Biotech
$1.82
At close - Nov 17, 4:00 PM EST - USD
Market Cap$877970
P/E-0.1x
52W High$23.80
Volume7.56K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Commercial Stagnation Masks Deep Structural Financial Erosion

Nexentis Technologies faces a critical inflection point as its commercial operations have effectively ceased, evidenced by a -100% year-over-year revenue decline in 2026Q1.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

NXTS price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

0/12 Beats

EPS beat 0 of last 12 quarters

02

Valuation risk

-101% Peers

P/E is 101% below peer median

03

Market leadership

RS 24 · Lag

Laggard (Underperforming 76% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 16
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue growth has plummeted to -100% in 2026Q1, while SG&A expenses of $1.9 million continue to outpace the company's negative gross profit.

Analyst Consensus
Hold(0 analysts)
0 Buy0 Hold0 Sell

The Bull Case

Upside Catalysts

SEC filings transparency

N2OFF, Inc. provides detailed SEC filings, including 10-K and 10-Q forms, enhancing investor transparency and trust.

Strategic business deals

Recent 8-K filings highlight key deals such as MitoCareX and Save Foods partnerships, indicating growth initiatives.

Reverse split execution

The company has executed a reverse split, which may improve stock liquidity and attract institutional investors.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
NXTS-83.63%
S&P 500 (^GSPC)+7.21%
1-Year Return
NXTS-34.68%
S&P 500 (^GSPC)+10.03%
3-Year Return
NXTS-97.52%
S&P 500 (^GSPC)+60.43%
5-Year Return
NXTS-99.90%
S&P 500 (^GSPC)+55.61%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$4M+22.9% YoY
Free cash flow FY25
-$4M-11.8% YoY
Operating margin FY25
-
ROIC (FY25)-41.6%
Avg ROIC 5Y-228.2%
ROE (TTM)-81.7%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 16, 2026
-$0.33
vs —
—
vs —
Q3 2026
Aug 13, 2026
-$129.80
vs —
—
vs —
Q2 2026
May 14, 2026
-$12.10
vs —
—
vs —
Q4 2025
Nov 13, 2025
$3.15
vs —
$2,000
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

2 Stories
Globe News Wire·1d ago
Nexentis: MitoCareX Progresses Toward In-Vitro Evaluation Following AI-Powered Computational Screening

Further computational prioritization by MitoCareX leads to selection and ordering of molecules for planned experimental assessment Ness Ziona, Israel,, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company") today announced that its wholly owned subsidiary, MitoCareX Bio Ltd.

GlobeNewsWire·Nov 5, 2026
Nexentis Announces Reverse Stock Split

Ness Ziona, Israel, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, announced that its Board of Directors has approved a one-for-five (1-for-5) reverse stock split of its common stock that is scheduled to become effective for Nasdaq purposes on November 9, 2026. Beginning on November 9, 2026, the Company's common stock will trade on the Nasdaq Capital Market on a split adjusted basis under a new CUSIP number 80512Q709. The Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol “NXTS.” As previously disclosed, at the Special Meeting of the Stockholders of Nexentis held on April 30, 2026, the Company's stockholders approved a proposal authorizing the Company's Board of Directors, among other things, to effect one or more reverse stock splits at a ratio of not less than 1-for-2 and not more than 1-for-500 in order to increase the per share price and bid price of the Company's common stock to regain compliance with the continued listing requirements of Nasdaq and make the common stock more attractive to certain institutional investors, which would provide for a stronger investor base.

Filtered for Nexentis Technologies Inc.More Headlines
04

Compare before deciding

Benchmark NXTS against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Nexentis Technologies Inc. (NXTS)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
NXTS logoNXTSNexentis Technologies Inc.Current
$1.82$877.97K-0.08-100%—-81.74%—
AMTX logoAMTXAemetis, Inc.
$1.09$76.7M-2.53-22.29%-12.04%——
GEVO logoGEVOGevo, Inc.
$1.64$399.19M-2.17849.33%-83.68%-48.1%—
PESI logoPESIPerma-Fix Environmental Services, Inc.
$13.42$284.55M-12.484.33%-39.55%-52.39%—
BIOA logoBIOABioAge Labs Inc.
$5.10$192.01M-2.17—-1253.6%-31.42%—
LOOP logoLOOPLoop Industries, Inc.
$0.21$10.37M-0.86-95.28%-2154.12%——

Compare NXTS vs Peers

Nexentis Technologies Inc. (NXTS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs AMTX

Most directly comparable listed peer for NXTS.

Scale Benchmark

vs NTR

Larger-name benchmark to compare NXTS against a more recognizable public peer.

Peer Set

Compare Top 5

vs AMTX, GEVO, PESI, BIOA

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

NXTS SEC Filings & Documents

Nexentis Technologies Inc. (NXTS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 6, 2026·SEC

Material company update

Oct 19, 2026·SEC

Material company update

Oct 6, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 31, 2026·SEC

FY 2025

Mar 31, 2025·SEC

10-Q Quarterly Reports

5
FY 2026

Aug 13, 2026·SEC

FY 2026

May 14, 2026·SEC

FY 2025

Nov 13, 2025·SEC

Get notified when NXTS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

NXTS Frequently Asked Questions

Nexentis Technologies Inc. (NXTS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Nexentis Technologies Inc.'s revenue?

Nexentis Technologies Inc. (NXTS) reported $-0.1M in revenue over the trailing twelve months.

How fast is Nexentis Technologies Inc. growing?

Nexentis Technologies Inc. (NXTS) revenue fell by 132.6% over the trailing twelve months, compared with the twelve months before.

Is NXTS profitable?

No. Nexentis Technologies Inc. (NXTS) reported a net loss of $11.4M over the trailing twelve months.

Dividend & Returns
What is NXTS's return on equity?

Nexentis Technologies Inc. (NXTS) had a return on equity (ROE) of -81.7% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Nexentis Technologies Inc.'s free cash flow?

Nexentis Technologies Inc. (NXTS) had negative free cash flow of $4.4M over the trailing twelve months.

What if you invested $1,000 in NXTS back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →